|
Market Closed -
Other stock markets
|
After hours 19:55:12 | |||
| 208.45 USD | +1.27% |
|
213.36 | +2.36% |
| 07-09 | Resmed Insider Sold Shares Worth $1,090,771, According to a Recent SEC Filing | MT |
| 07-09 | Jarden Adjusts ResMed's Price Target to AU$40.20 from AU$42.70, Keeps at Overweight | MT |
Company Valuation: ResMed, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: June | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 35,903 | 30,691 | 32,133 | 28,117 | 37,762 | 30,067 | - | - |
| Change | - | -14.52% | 4.7% | -12.5% | 34.31% | -20.38% | - | - |
| Enterprise Value (EV) 1 | 36,263 | 31,192 | 33,346 | 28,585 | 37,221 | 29,218 | 28,479 | 27,613 |
| Change | - | -13.98% | 6.9% | -14.28% | 30.21% | -21.5% | -2.53% | -3.04% |
| P/E | 76.1x | 39.6x | 35.9x | 27.7x | 27.1x | 19.7x | 18.5x | 16.5x |
| PBR | 12.4x | 9.35x | 7.76x | 5.78x | 6.33x | 4.62x | 4.29x | 3.97x |
| PEG | - | 0.6x | 2.4x | 2x | 0.7x | 1.7x | 2.84x | 1.4x |
| Capitalization / Revenue | 11.2x | 8.58x | 7.61x | 6x | 7.34x | 5.32x | 5.03x | 4.7x |
| EV / Revenue | 11.3x | 8.72x | 7.9x | 6.1x | 7.23x | 5.17x | 4.77x | 4.32x |
| EV / EBITDA | 33.8x | 26.8x | 25.3x | 18.1x | 19.8x | 13.3x | 12.2x | 10.9x |
| EV / EBIT | 40.1x | 31.2x | 27.2x | 19.3x | 21.1x | 14.4x | 13.1x | 11.7x |
| EV / FCF | 57.2x | 144x | 58.1x | 22x | 22.4x | 18.1x | 16.9x | 15.6x |
| FCF Yield | 1.75% | 0.69% | 1.72% | 4.55% | 4.46% | 5.53% | 5.9% | 6.42% |
| Dividend per Share 2 | 1.56 | 1.68 | 1.8 | 1.92 | 2.12 | 2.435 | 2.643 | 2.628 |
| Rate of return | 0.63% | 0.8% | 0.82% | 1% | 0.82% | 1.17% | 1.27% | 1.26% |
| EPS 2 | 3.24 | 5.3 | 6.09 | 6.92 | 9.51 | 10.6 | 11.3 | 12.63 |
| Distribution rate | 48.1% | 31.7% | 29.6% | 27.7% | 22.3% | 23% | 23.4% | 20.8% |
| Net sales 1 | 3,197 | 3,578 | 4,223 | 4,685 | 5,146 | 5,650 | 5,974 | 6,399 |
| EBITDA 1 | 1,074 | 1,162 | 1,317 | 1,576 | 1,884 | 2,192 | 2,342 | 2,531 |
| EBIT 1 | 903.7 | 1,000 | 1,224 | 1,478 | 1,763 | 2,033 | 2,175 | 2,357 |
| Net income 1 | 474.5 | 779.4 | 897.6 | 1,021 | 1,401 | 1,549 | 1,650 | 1,830 |
| Net Debt 1 | 360.1 | 501.5 | 1,213 | 468.9 | -541.2 | -849.1 | -1,588 | -2,454 |
| Reference price 2 | 246.52 | 209.63 | 218.50 | 191.42 | 258.00 | 208.45 | 208.45 | 208.45 |
| Nbr of stocks (in thousands) | 145,640 | 146,405 | 147,062 | 146,884 | 146,365 | 144,240 | - | - |
| Announcement Date | 8/5/21 | 8/11/22 | 8/3/23 | 8/1/24 | 7/31/25 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 19.66x | 5.17x | 13.33x | 1.17% | 30.07B | |
| 26.27x | 4.73x | 18.22x | 0.35% | 195B | |
| 45.51x | 11.84x | 26.5x | -.--% | 146B | |
| 16.53x | 3.43x | 11.05x | -.--% | 66.87B | |
| 32.57x | 7.28x | 23.14x | -.--% | 52.59B | |
| 18.15x | 2.09x | 10.82x | 2.89% | 43.85B | |
| 25.95x | 5.17x | 17.68x | 0.77% | 37.73B | |
| 45.71x | 6.38x | 19.59x | -.--% | 37.03B | |
| 14.53x | 1.62x | 9.08x | 0.24% | 29.43B | |
| 41.34x | 6.53x | 23.23x | -.--% | 29.32B | |
| Average | 28.62x | 5.42x | 17.26x | 0.54% | 66.76B | |
| Weighted average by Cap. | 30.37x | 6.26x | 18.85x | 0.4% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- RMD Stock
- Valuation ResMed, Inc.
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
